Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. This is a metadata version change and does not alter the study details displayed.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check19 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.0%

- Check41 days agoChange Detected- Revision: v3.3.4 updated (replacing v3.3.3). The overall study information on the page remains unchanged.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded a Locations section with a comprehensive list of study sites across the US and Australia; previous location entries were removed.SummaryDifference1%

- Check91 days agoChange DetectedPublications note updated to say PubMed publications are automatically filled from PubMed, and the revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check99 days agoChange DetectedThe page no longer displays the government-funding operating-status notice; core study information such as the title, eligibility, and locations remains unchanged.SummaryDifference0.1%

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.